> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review CV Risk Assessments with Diabetes Drugs
- URL: https://www.fdaweb.com/panel-to-review-cv-risk-assessments-with-diabetes-drugs/
- Published: 2018-09-18T12:00:00.000Z
- Updated: 2026-09-15T00:32:32.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142377

*Federal Register* notice: FDA has announced a 10/24-25 Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the agency’s “[Guidance for Industry](https://www.fda.gov/%20downloads/Drugs/Guidances/%20ucm071627.pdf?ref=fdaweb.com): Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.” The agency is promoting the panel meeting as a review of what it has learned the last decade, and consideration on how to move forward with cardiovascular risk assessment for future glucose lowering therapies. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-09-18/pdf/2018-20233.pdf?ref=fdaweb.com).